Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm Clinical Trial

Official title:

A Phase II Study Of Genasense In Combination With Thalidomide And Dexamethasone In Relapsed And Refractory Multiple Myeloma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00049374
• Other study ID #: CDR0000258058
• Secondary ID: MSGCC-210421NCI-
• Status: Completed
• Phase: Phase 2
• Start date: September 2002
• Est. completion date: January 2006

Study information

• Verified date: October 2019
• Source: University of Maryland, Baltimore
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Thalidomide may slow the growth of cancer cells. Oblimersen may increase the effectiveness of thalidomide and dexamethasone by making cancer cells more sensitive to the drugs.

PURPOSE: Phase II trial to study the effectiveness of combining thalidomide and dexamethasone with oblimersen in treating patients who have relapsed or refractory multiple myeloma.

Description:

OBJECTIVES:

• Determine the clinical efficacy of oblimersen, thalidomide, and dexamethasone, in terms of complete and partial response rates, in patients with relapsed or refractory multiple myeloma.

• Determine the time to progression and duration of response in patients treated with this regimen.

• Determine the toxicity of this regimen in these patients.

• Correlate disease response (clinical outcome) with changes in Bcl-2 levels in patients treated with this regimen.

• Determine the disease-free and overall survival of patients treated with this regimen.

OUTLINE: Patients receive induction therapy comprising oblimersen IV continuously on days 1-7, 22-28, and 43-49, oral dexamethasone on days 4-7, 25-28, and 46-49, and oral thalidomide daily beginning on day 4. Treatment continues in the absence of disease progression or unacceptable toxicity.

Patients with stable disease after induction therapy receive maintenance therapy comprising oblimersen IV continuously on days 1-7, oral dexamethasone on days 4-7, and oral thalidomide daily. Courses repeat every 35 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

Patients are followed for 3 years.

PROJECTED ACCRUAL: A total of 10-46 patients will be accrued for this study within 10 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Est. completion date: January 2006
• Est. primary completion date: January 2006
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 120 Years

Eligibility

DISEASE CHARACTERISTICS:

• Histologically and clinically confirmed multiple myeloma

• Relapsed and/or refractory after chemotherapy or transplantation

• Patients with prior allogeneic transplantation must not have evidence of active graft-vs-host disease requiring immune suppression

• Measurable disease defined by quantitative immune globulin levels in serum and/or urine and bone marrow plasmacytosis

• Patients with nonsecretory disease are eligible provided at least 1 plasmacytoma lesion is accurately measurable by MRI or CT scan

• No known CNS involvement

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• ECOG 0-2 OR

• Karnofsky 60-100%

Life expectancy

• More than 3 months

Hematopoietic

• See Disease Characteristics

• Absolute neutrophil count at least 1,000/mm^3*

• Platelet count at least 50,000/mm^3* NOTE: *Unless secondary to bone marrow plasmacytosis (more than 80% involvement)

Hepatic

• Bilirubin less than 2 times normal

• AST/ALT no greater than 3 times upper limit of normal

Renal

• Creatinine no greater than 2 mg/dL

Cardiovascular

• No symptomatic congestive heart failure

• No unstable angina pectoris

• No cardiac arrhythmia

Other

• Seizures allowed if under adequate control

• No severe skin reactions from prior thalidomide

• No prior allergic reactions attributed to agents used in this study

• No sensory or motor neuropathy grade II or greater

• No other uncontrolled concurrent illness that would preclude study therapy

• No ongoing or active infection

• No psychiatric illness or social situations that would preclude study compliance

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use 2 effective methods of contraception for 1 month before, during, and for 1 month after study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy

• See Disease Characteristics

• See Chemotherapy

• At least 6 weeks since prior thalidomide

Chemotherapy

• See Disease Characteristics

• No more than 4 prior chemotherapy regimens, including autologous and/or allogeneic stem cell transplantation regimens

• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered

Endocrine therapy

• Concurrent continuous steroids allowed for chronic treatment of disorders other than myeloma

Radiotherapy

• Not specified

Surgery

• Not specified

Other

• No prior oblimersen

• No other concurrent anticancer therapies or investigational agents

• No concurrent combination antiretroviral therapy for HIV-positive patients

Related Conditions & MeSH terms

• Multiple Myeloma
• Multiple Myeloma and Plasma Cell Neoplasm
• Neoplasms, Plasma Cell
• Plasmacytoma

Intervention

Biological:
• oblimersen sodium

Drug:
• dexamethasone

• thalidomide

Locations

Country	Name	City	State
United States	Greenebaum Cancer Center at University of Maryland Medical Center	Baltimore	Maryland
United States	St. Vincent's Comprehensive Cancer Center - Manhattan	New York	New York

Sponsors (3)

Lead Sponsor	Collaborator
University of Maryland, Baltimore	National Cancer Institute (NCI), University of Maryland Greenebaum Cancer Center

Country where clinical trial is conducted

United States, 

References & Publications (1)

Badros AZ, Goloubeva O, Rapoport AP, Ratterree B, Gahres N, Meisenberg B, Takebe N, Heyman M, Zwiebel J, Streicher H, Gocke CD, Tomic D, Flaws JA, Zhang B, Fenton RG. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexameth — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete and partial remission
Secondary	Relationship between molecular and clinical outcomes